AbbVievs.Pfizer
ABBV vs PFE · both in Big pharma, part of the Medicine, pharma & life science value chain: Large, diversified pharmaceutical groups with broad portfolios across therapeutic areas.
AbbVie is about 2.9× larger than Pfizer by market cap; Pfizer trades at the lower P/E (35.2 vs 70.2); year to date, AbbVie leads (+15.8% vs +12.3%).
Side by side
| ABBV | PFE | |
|---|---|---|
| Market cap | $443B | $152B |
| Price | $265.79 | $28.57 |
| Today | +0.5% | +2.1% |
| Return YTD | +15.8% | +12.3% |
| Return 1Y | +25.6% | +8.1% |
| P/E | 70.2 | 35.2 |
| P/S | 6.9 | 2.4 |
| P/B | 312.1 | 1.8 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
AbbVieABBV
Skyrizi and Rinvoq carry the immunology franchise. Oncology and neuroscience follow, plus the aesthetics business built around Botox.
Full ABBV profile →PfizerPFE
Vaccines are what most people associate with Pfizer. The portfolio is considerably broader: oncology is a large part of it, and internal medicine covers much of the rest.
Full PFE profile →More ABBV & PFE comparisons
Other head-to-heads in the Big pharma segment.
See where ABBV and PFE sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →